Find practical information about diabetes treatment and management, including blood sugar monitoring, medications, lifestyle changes, complications and everyday diabetes care.
Pharmaceutical giant Eli Lilly launches an ambitious programme to extend its obesity and diabetes treatments to low- and middle-income countries by 2040, aiming to close access gaps and build lasting healthcare infrastructure. Eli Lilly is trying to turn its dominance…
Researchers highlight a dramatic rise in GLP-1 medication prescriptions among new mothers in the US, sparking concerns over safety during breastfeeding despite rapid adoption for weight management and diabetes care. Researchers at the University of Southern California say prescriptions for…
Effective support for children with type 1 diabetes in schools hinges on comprehensive planning, staff training, and personalised accommodations to navigate unpredictable mealtimes and daily challenges. Children with type 1 diabetes can make school work, but the term “work” matters.…
Kips Bio Med unveils preclinical data at EASD meeting demonstrating its innovative oral insulin platform can be customised for faster absorption, potentially revolutionising oral therapies for diabetes and obesity. Kips Bio Med, the subsidiary of South Korean biotech group Kips…
Eli Lilly reports stronger-than-expected outcomes from its experimental combination therapy EloraTZP, potentially expanding its dominance in cardiometabolic medicine and accelerating its path to late-stage trials. Eli Lilly said on Tuesday that a mid-stage trial of its experimental obesity and diabetes…
Novo Nordisk has agreed to licence HRS-1596, an innovative phase I-ready oral dual agonist for obesity and diabetes from Hengrui Pharma, signalling a push to expand oral metabolic therapies amidst fierce industry competition. Novo Nordisk has agreed to license HRS-1596,…
Honor’s new Watch 6 Pro in China boasts advanced health features, but claims around blood sugar and cardiac arrest alerts are more nuanced than they appear, highlighting the importance of regulatory context and technological reality. Honor’s new Watch 6 Pro…
Eli Lilly’s experimental drug retatrutide delivers significant weight loss and blood sugar improvements in phase 3 trials, potentially transforming treatment for obesity and type 2 diabetes, with regulatory approval sought in 2027. Retatrutide, an experimental obesity and diabetes drug being…
World Heart Day highlights the overlooked high risk of cardiovascular disease in Asian American, Native Hawaiian, and Pacific Islander communities, prompting updated clinical strategies to improve detection and treatment tailored to diverse ethnic groups. World Heart Day is drawing attention…
The Spanish network redGDPS highlights its commitment to advancing diabetes care through online resources and practical guidance at the EASD annual congress, reinforcing its role in supporting primary care professionals with innovative tools and training. The European Association for the…
Emerging evidence suggests that magnesium depletion may be associated with increased inflammation and risk of foot ulcers in people with diabetes, raising questions about the potential role of magnesium supplementation in prevention and treatment. Low magnesium levels may be more…
Huawei announces a new method to measure blood glucose without finger-pricks, but the technology faces scientific and regulatory challenges before reaching consumers. Huawei has said it has developed a way to measure blood glucose without a finger-prick after four years…
